Jubilant Pharmova’s Second-Quarter Profit Figures Could Not Be Verified
Key Facts
Jubilant Pharmova’s second-quarter fiscal 2026-27 figures could not be verified against a reliable public filing, so reports of a profit decline or revenue growth for the period cannot be confirmed. The company’s financial results page lists first-quarter results, with no visible disclosure for the second quarter. In its latest published results, the company said first-quarter revenue was 2,229 crore rupees, up 17% year on year. EBITDA was about 268 crore rupees in the quarter, according to the company’s announcement. These figures provide context for the company’s performance, but they relate to the first quarter and do not establish figures for the more recent period.
In radiopharmaceuticals, revenue rose 19% to 322 crore rupees in the first quarter of fiscal 2026-27, while EBITDA was 110 crore rupees, the company said. Jubilant Pharmova said the segment’s margins fell year on year because some SPECT products were unavailable. The company also attributed the first-quarter margin decline to the unavailability of high-margin radiopharmaceutical SPECT products, along with low third-party revenue and higher operating expenses. Additional expenses included processing costs at the Montreal facility of its contract manufacturing operations, according to the results announcement. These factors relate to first-quarter performance and do not provide a documented explanation for any figures circulating for the second quarter.
The company said commercial batch production of SPECT products began after successful media-fill tests, and that it expected to launch those batches in the second quarter of fiscal 2026-27. It added that all SPECT products were expected to be available by the second half of the fiscal year. Separately from that outlook, the company said radiopharmaceutical revenue grew 19% in the first quarter to 322 crore rupees. Segment EBITDA was 110 crore rupees in the same period. The company expected EBITDA margin expansion to begin in the second half of fiscal 2026-27, after attributing first-quarter pressure to product availability and operating costs.
Second-quarter figures from the previous fiscal year provide a historical comparison: Jubilant Pharmova’s revenue then rose 12% year on year to 1,966 crore rupees. Adjusted profit after tax also increased 21% to 124 crore rupees in the second quarter of fiscal 2025-26, according to company announcements. These figures relate to the comparable period of the previous fiscal year and do not confirm the revenue or profit figures circulating for the current second quarter. An official disclosure of second-quarter results is still needed to establish performance for the period and make a year-on-year comparison. Until that disclosure is available, figures attributed to the current second quarter cannot be presented as confirmed results.